The promise and harms of screening for plasma cell dyscrasias-Reference-Cited by-同舟云学术

The promise and harms of screening for plasma cell dyscrasias

Published:2023-01-10 Issue:6 Volume:200 Page:704-707
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mohyuddin Ghulam Rehman¹^ORCID,Chakraborty Rajshekhar²,Cliff Edward R. Scheffer³

Affiliation:

1. Division of Hematology and Hematological Malignancies Huntsman Cancer Institute, University of Utah Salt Lake City Utah USA

2. Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center New York New York USA

3. Program on Regulation Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA

Abstract

SummaryIn this perspective, we highlight both the promise and harms of screening for plasma cell dyscrasias, as well as the implications of the use of mass spectrometry for diagnosing monoclonal gammopathy of undetermined significance in routine practice.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18634

Reference23 articles.

1. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

2. Screening for Cervical Cancer

3. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance

4. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

5. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey;eClinicalMedicine;2023-11